A pressed-herbarium reading-room on the BPC-157 + TB-500 'Wolverine' blend — the two peptides set down as specimen plates, the regulatory and 503A-compounding-access record annotated in the field-book margin.
MD Wolverine
A hand-drawn pressed-herbarium plate of two abstract peptide molecular specimens — a long ribbon and a short loop — mounted under a botanical halo in faded brick and goldenrod on a deep herb-green leaf

A pressed herbarium of two peptides

BPC-157 TB-500 is the two-peptide Wolverine research blend, studied for tissue repair across animal models.

Two distinct peptides mounted as two specimens: a 15-residue body-protection compound beside a 7-residue actin-binding fragment. Here is what the published literature on each actually establishes — and where the combination's evidence stops.

Read the researchThe regulatory & access record

What the Wolverine blend is — and is not

BPC-157 TB-500 is a two-peptide pairing the research community calls the "Wolverine" blend, discussed as a tissue-repair stack. It is not a single molecule, not an approved medicine, and not a co-formulation with a validated composition. It is two synthetic peptides, mounted side by side, each carrying its own thirty-year paper trail.

The first specimen is BPC-157 — Body Protection Compound 157 — a 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, molecular weight roughly 1,419.5 Da) derived from a partial sequence of a protein found in human gastric juice [1]. The second is TB-500, a synthetic N-acetylated heptapeptide (Ac-LKKTETQ, roughly 889.0 Da) corresponding to residues 17-23 — the actin-binding region — of the 43-residue protein Thymosin Beta-4 [7].

That second provenance carries a caveat worth pinning to the page early. The "TB-500" sold and stacked is the seven-residue fragment, but the overwhelming majority of efficacy data attributed to it were generated with full-length Thymosin Beta-4 (~4,963 Da), not the 7-mer [4]. The blend inherits that gap: it leans on full-protein data for one of its two legs. Everything that follows is a digest of the published record on each constituent — not a protocol, not a recommendation, and not a claim about the combination that the literature has not made.

BPC-157 and TB-500: the two peptides in the Wolverine blend

BPC-157 and TB-500 are paired because they are described as acting through complementary but largely non-overlapping pathways — which is the entire basis of the "synergy" claim, and also its limit [4].

BPC-157 supplies the cytoprotective and pro-angiogenic leg. In preclinical models it up-regulates VEGFR2 and promotes its internalization, driving the VEGFR2-Akt-eNOS pathway, and it modulates the nitric-oxide system [2]. In a transected rat Achilles tendon it improved load-to-failure, collagen organization, and tendon integrity versus untreated controls, dosed at 10 µg/kg or 10 ng/kg intraperitoneally [1].

TB-500 supplies the cytoskeletal leg. Its LKKTETQ motif binds monomeric G-actin in a 1:1 complex, regulating the actin dynamics that drive cell migration [3]. Thymosin Beta-4 — the parent protein — binds actin, mobilizes cells, decreases myofibroblast number, limits inflammation after injury, and promotes angiogenesis [4]. The structural basis is settled: X-ray crystallography of a gelsolin-domain-1-Tbeta4 hybrid bound to actin established that thymosin beta-4 sequesters the G-actin monomer by capping both ends, preventing polymerization [3].

The BPC-157 TB-500 research findings sit on the research page; the TB-500 actin mechanism is set down in detail on its own plate, including how TB-500 sequesters G-actin.

What is the difference between BPC-157 and TB-500?

They are two different peptides with two different jobs. BPC-157 is a 15-residue pentadecapeptide that supplies a local cytoprotective and angiogenic signal through VEGFR2-Akt-eNOS [2]. TB-500 is a 7-residue actin-binding fragment that sequesters G-actin to regulate cell migration [3]. One signals vessels and tissue protection; the other signals the cytoskeleton. Their pathways are described as complementary, not shared [4].

What is the Wolverine peptide blend?

It is a research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed and marketed as a tissue-repair "stack." It is not a single chemical entity, has no CAS number or molecular weight of its own, and is not an approved product. Commercial vials are commonly labeled with a combined per-vial mass (for example, 10 mg + 10 mg), but no standardized ratio is clinically validated [4].

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid pentadecapeptide from a human gastric-juice protein; TB-500 is the synthetic Ac-LKKTETQ fragment of Thymosin Beta-4. The blend pairs them as a tissue-repair stack. BPC-157 is studied as a cytoprotective, pro-angiogenic agent [1][2]; TB-500 as an actin-sequestering, cell-migration agent [3].

Why the BPC-157 + TB-500 stack is combined

The rationale behind the BPC-157 TB-500 stack is mechanistic complementarity. BPC-157's angiogenic and cytoprotective signal is paired with TB-500's cytoskeletal-migration signal, on the theory that the two repair levers add up to more than either alone [4].

The honest framing matters: this is a theoretical extrapolation from each peptide's independently characterized mechanism, not a finding from a controlled combination study. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two given together. A 2025 systematic review of BPC-157 in orthopaedic sports medicine — 36 studies, only one of them human — makes no mention of TB-500 or any combination at all [8].

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

Because their mechanisms are described as complementary: BPC-157's angiogenic and cytoprotective signal plus TB-500's cytoskeletal-migration signal [4]. The pairing is a theoretical extrapolation from two separately characterized pathways, not a result demonstrated in a controlled combination study [8]. The "synergy" is a hypothesis the literature has not tested.

For the regulatory picture, see the FDA and WADA status of BPC-157 and TB-500, and for the unproven-pairing question, the combination synergy claim.

What the record establishes, and what it does not

The evidence for both constituents is overwhelmingly preclinical and rodent. BPC-157 has only three small human pilot studies; the TB-500 fragment has zero completed controlled human trials, and the human data that exist for "TB-500" are on full-length Thymosin Beta-4, not the 7-mer [4]. The combination's human efficacy and safety are unproven.

Newer reviews keep the narrative bounded. A 2026 Sports Medicine review of approved and unapproved musculoskeletal peptides — which lists both BPC-157 and TB-500 — concludes that many unapproved peptides show favorable tissue-repair outcomes in animals but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [9].

Two caveats sit at the center of the blend and recur throughout this site. The first is provenance: the marketed "TB-500" is the seven-residue Ac-LKKTETQ fragment, but most of its claimed effects were measured on the full-length protein [4]. The second is composition: "Wolverine" material is distributed through non-regulated channels, so product identity, purity, and the actual BPC-157:TB-500 ratio are unverified outside formal studies [4]. Neither caveat is a verdict against the underlying science; both are reasons to read each claim against its exact source.

This site is a reading room, not a clinic. It mounts each specimen with its label and its caveat. The frequently asked questions about the blend collect the common queries; the BPC-157 TB-500 dosage in the literature is reported strictly as administered to species in studies, never as guidance.